Imlifidase

From Wikipedia, the free encyclopedia

Imlifidase
Clinical data
Pronunciationim lif' i dase
Trade namesIdefirix
Other namesHMED-IdeS
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • EU: Rx-only [1]
Identifiers
CAS Number
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC1575H2400N422O477S6
Molar mass35071.36 g·mol−1

Imlifidase, brand name Idefirix, is a medication for the desensitization of highly sensitized adults needing kidney transplantation, but unlikely to receive a compatible transplant.[1]

Imlifidase is a cysteine protease derived from the immunoglobulin G (IgG)‑degrading enzyme of Streptococcus pyogenes.[1] It cleaves the heavy chains of all human IgG subclasses (but no other immunoglobulins), eliminating Fc-dependent effector functions, including CDC and antibody-dependent cell-mediated cytotoxicity (ADCC).[1] Thus, imlifidase reduces the level of donor specific antibodies, enabling transplantation.[1]

The benefits with imlifidase are its ability to convert a positive crossmatch to a negative one in highly sensitized people to allow renal transplantation.[1] The most common side effects are infections and infusion related reactions.[1]

Imlifidase was approved for medical use in the European Union in August 2020.[1][2]

Medical uses[edit]

Imlifidase is indicated for desensitization treatment of highly sensitized adult kidney transplant people with positive crossmatch against an available deceased donor.[1] The use of imlifidase should be reserved for people unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized people.[1]

History[edit]

Imlifidase was granted orphan drug designations by the European Commission in January 2017, and November 2018,[3][4] and by the U.S. Food and Drug Administration (FDA) in both February and July 2018.[5][6]

In February 2019, Hansa Medical AB changed its name to Hansa Biopharma AB.[4]

References[edit]

  1. ^ a b c d e f g h i j "Imlifidase: EPAR". European Medicines Agency (EMA). 25 June 2020. Archived from the original on 24 October 2020. Retrieved 24 September 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ "New treatment to enable kidney transplant in highly sensitized patients". European Medicines Agency (Press release). 26 June 2020. Archived from the original on 29 June 2020. Retrieved 26 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ "EU/3/16/1826". European Medicines Agency (EMA). 12 January 2017. Archived from the original on 29 June 2020. Retrieved 27 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b "EU/3/18/2096". European Medicines Agency (EMA). 13 February 2019. Archived from the original on 28 June 2020. Retrieved 27 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Imlifidase Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 3 July 2018. Archived from the original on 29 June 2020. Retrieved 27 June 2020.
  6. ^ "Imlifidase Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 14 February 2018. Archived from the original on 28 June 2020. Retrieved 27 June 2020.

Further reading[edit]

External links[edit]

  • "Imlifidase". Drug Information Portal. U.S. National Library of Medicine.